PAVmed (PAVM) Set to Release Quarterly Earnings on Friday

PAVmed (NASDAQ:PAVM) is projected to post its Q3 2026 results before the market opens on Friday, November 13th. Analysts expect the company to post earnings of ($0.66) per share and revenue of $0.03 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

PAVmed Trading Down 4.3%

Shares of PAVmed stock opened at $1.56 on Wednesday. PAVmed has a fifty-two week low of $1.41 and a fifty-two week high of $28.44. The business’s fifty day moving average is $3.09 and its two-hundred day moving average is $6.32. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.19 and a quick ratio of 1.19.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $56.00.

About PAVmed

PAVmed Inc. is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care. One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease.